Elevated tumor markers, such as carbohydrate antigen 19–9, carcinoembryonic antigen (CEA), sialylated pancreatic antigen-1, and Duke pancreatic monoclonal antigen type 2, have been observed in patients with cPDAC. This evidence concerns the gene CEACAM5 and neoplasm.